Neonatal Anemia.
Study Goal
The researchers aimed to review the mechanisms of physiologic anemia and anemia of prematurity in neonates and evaluate treatment options, including iron supplementation.
Results Summary
The abstract highlights the pronounced drop in hematocrit in critically ill and preterm neonates, leading to pathologic anemia, and briefly reviews evidence for treatments such as iron supplementation, but does not provide specific outcomes for iron's effects.
Population
Critically ill and preterm neonates
Effective Dosage
Not available
Duration
Not specified
Interactions
None mentioned
| Intervention | Direction | Endpoint | Population | Dosage | Impact | Claim # |
|---|---|---|---|---|---|---|
- | decrease | hematocrit values | All neonates | - | experience a downtrend | #1 |
- | decrease | erythropoietin (Epo) production | neonates | - | normal falls | #2 |
- | decrease | this drop | critically ill and preterm neonates | - | more pronounced | #3 |
red blood cell transfusions | neutral | anemia | neonatal population | - | treatment of anemia | #4 |
erythropoietic stimulating agents | neutral | anemia | neonatal population | - | treatment of anemia | #5 |
iron supplementation | neutral | anemia | neonatal population | - | treatment of anemia | #6 |
All neonates experience a downtrend in their hematocrit values immediately following the birth through normal falls in erythropoietin (Epo) production, transition to adult hemoglobin, and hemodilution with somatic growth. However, this drop is more pronounced in critically ill and preterm neonates and can lead to potentially pathologic anemia that impairs tissue oxygen delivery. In this review, we highlight the mechanisms underlying physiologic anemia and anemia of prematurity and briefly review the evidence for the treatment of anemia in the neonatal population, including the use of red blood cell transfusions, erythropoietic stimulating agents, and iron supplementation.